EPS for CytomX Therapeutics, Inc. (CTMX) Expected At $-0.40

October 13, 2018 - By Hazel Jackson

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Logo

Analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to report $-0.40 EPS on November, 6.They anticipate $0.12 EPS change or 42.86 % from last quarter’s $-0.28 EPS. After having $-0.35 EPS previously, CytomX Therapeutics, Inc.’s analysts see 14.29 % EPS growth. The stock increased 3.07% or $0.47 during the last trading session, reaching $15.79. About 434,303 shares traded or 4.74% up from the average. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has risen 16.94% since October 13, 2017 and is uptrending. It has outperformed by 1.32% the S&P500.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States. The company has market cap of $709.98 million. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. It currently has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.

More recent CytomX Therapeutics, Inc. (NASDAQ:CTMX) news were published by: Globenewswire.com which released: “CytomX Therapeutics Announces Presentations at 2018 ESMO Annual Meeting” on October 08, 2018. Also Seekingalpha.com published the news titled: “Key events next week – healthcare” on October 12, 2018. Nasdaq.com‘s news article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX …” with publication date: October 12, 2018 was also an interesting one.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>